Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02024646 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 484
- Enrollment target
NCT02024646 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 484 participants.
The verdict
NCT02024646, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 484 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.
Interventions
- DRUG Placebo
- DRUG 210 mg brodalumab
- DRUG 140 mg brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02024646
The ClinicalTrials.gov registry entry for NCT02024646 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02024646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02024646 about?
NCT02024646 is a clinical study titled "Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis". The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety...
What is the current status of trial NCT02024646?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 484 participants. The study started on 2014-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02024646?
The interventions under investigation include: Placebo (DRUG), 210 mg brodalumab (DRUG), 140 mg brodalumab (DRUG).
Who is sponsoring clinical trial NCT02024646?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.